Routine blood test markers for predicting liver disease post HBV infection: precision pathology and pattern recognition
Author:
Ajuwon Busayo I.12, Roper Katrina1, Richardson Alice3, Lidbury Brett A.1
Affiliation:
1. National Centre for Epidemiology and Population Health , ANU College of Health and Medicine, The Australian National University , Acton , Australian Capital Territory , Australia 2. Department of Microbiology , Faculty of Pure and Applied Sciences, Kwara State University , Malete , Nigeria 3. Statistical Support Network , The Australian National University , Acton , Australian Capital Territory , Australia
Abstract
Abstract
Background
Early stages of hepatitis B virus (HBV) infection usually involve inflammation of the liver. Patients with chronic infection have an increased risk of progressive liver fibrosis, cirrhosis, and life-threatening clinical complications of end-stage hepatocellular carcinoma (HCC).
Content
Early diagnosis of hepatic fibrosis and timely clinical management are critical to controlling disease progression and decreasing the burden of end-stage liver cancer. Fibrosis staging, through its current gold standard, liver biopsy, improves patient outcomes, but the clinical procedure is invasive with unpleasant post-procedural complications. Routine blood test markers offer promising diagnostic potential for early detection of liver disease without biopsy. There is a plethora of candidate routine blood test markers that have gone through phases of biomarker validation and have shown great promise, but their current limitations include a predictive ability that is limited to only a few stages of fibrosis. However, the advent of machine learning, notably pattern recognition, presents an opportunity to refine blood-based non-invasive models of hepatic fibrosis in the future.
Summary
In this review, we highlight the current landscape of routine blood-based non-invasive models of hepatic fibrosis, and appraise the potential application of machine learning (pattern recognition) algorithms to refining these models and optimising clinical predictions of HBV-associated liver disease.
Outlook
Machine learning via pattern recognition algorithms takes data analytics to a new realm, and offers the opportunity for enhanced multi-marker fibrosis stage prediction using pathology profile that leverages information across patient routine blood tests.
Funder
Australian National Health and Medical Research Ideas Grant Australian Commonwealth Department of Health Quality Use of Pathology Programme RSTMH Early Career Grants Programme
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,Public Health, Environmental and Occupational Health,Health Policy,Medicine (miscellaneous)
Reference90 articles.
1. World Health Organization. Hepatitis B key facts; 2021. https://www.who.int/newsroom/factsheets/detail/hepatitis-b. 2. Friedman, SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655–69. https://doi.org/10.1053/j.gastro.2008.03.003. 3. Yang, L, Kwon, J, Popov, Y, Gajdos, GB, Ordog, T, Brekken, RA, et al.. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 2014;146:1339–50.e1. https://doi.org/10.1053/j.gastro.2014.01.061. 4. Golabi, P, Fazel, S, Otgonsuren, M, Sayiner, M, Locklear, CT, Younossi, ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine 2017;96:e5904. https://doi.org/10.1097/md.0000000000005904. 5. Heimbach, JK, Kulik, LM, Finn, RS, Sirlin, CB, Abecassis, MM, Roberts, LR, et al.. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358–80. https://doi.org/10.1002/hep.29086.
|
|